The South San Francisco company once headed by scorned biotech investor Martin Shkreli, and now wending its way through bankruptcy court, has a new CEO.
KaloBios Pharmaceuticals Inc. (OTC: KBIOQ) said in a Securities and Exchange Commission filing on Friday that it hired Dr. Cameron Durrant as CEO for $50,000 a month. Durrant has been a director and chairman of the reconstituted KaloBios board since Jan. 7.
Shkreli vaulted KaloBios to national prominence in November after leading a group of investors…The South San Francisco company once headed by scorned biotech investor Martin Shkreli, and now wending its way through bankruptcy court, has a new CEO.
KaloBios Pharmaceuticals Inc. (OTC: KBIOQ) said in a Securities and Exchange Commission filing on Friday that it hired Dr. Cameron Durrant as CEO for $50,000 a month. Durrant has been a director and chairman of the reconstituted KaloBios board since Jan. 7.
Shkreli vaulted KaloBios to national prominence in November after leading a group of investors…